What are the adverse effect profiles of tacrolimus, mycophenolate mofetil (MMF), and basiliximab when used for renal transplantation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 1, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Tacrolimus, Mycophenolate Mofetil (MMF), and Basiliximab in Renal Transplantation

Tacrolimus Side Effects

Tacrolimus carries an FDA black box warning for increased susceptibility to infection and possible development of lymphoma. 1

Common and Serious Adverse Effects

  • Nephrotoxicity is a major concern, causing dose-dependent renal insufficiency through afferent arteriolar vasoconstriction 1, 2
  • New-onset diabetes mellitus occurs in approximately 10.4% of tacrolimus-treated patients, making it more diabetogenic than cyclosporine 1
  • Hypertension is common and requires monitoring 1
  • Neurotoxicity manifests as headaches, tremors, neuropathy, and seizures 1
  • Hyperkalemia and hypomagnesemia are frequent electrolyte disturbances 1
  • Cardiac toxicity can occur 1
  • Bone marrow suppression may develop 1
  • Dyslipidemia is less common than with cyclosporine but still occurs 1

Gastrointestinal and Other Effects

  • Acne, dizziness, increased hair growth (less than cyclosporine) 1
  • Nausea, vomiting, diarrhea, and stomach discomfort 1
  • Numbness and tingling 1

Critical Drug Interactions

Tacrolimus is metabolized through the hepatic CYP3A4 system, making it highly susceptible to drug interactions 1:

  • Drugs that increase tacrolimus levels (and toxicity risk): azole antifungals (imidazoles), macrolide antibiotics, nondihydropyridine calcium channel blockers 1, 3
  • Drugs that decrease tacrolimus levels: rifampin, rifabutin, carbamazepine, phenobarbital, phenytoin, St. John's Wort 1
  • High-fat meals decrease oral absorption by 37% with a 77% decrease in maximum plasma concentration 1
  • NSAIDs potentiate nephrotoxicity and should be avoided 1
  • Spironolactone increases hyperkalemia risk 1

Pregnancy and Lactation

  • FDA pregnancy category C for all trimesters 1
  • Crosses the placenta but no confirmed teratogenic effects in humans 1
  • Enters breast milk and may cause immune suppression in nursing infants 1

Mycophenolate Mofetil (MMF) Side Effects

MMF has a more favorable safety profile than many immunosuppressants, with no nephrotoxicity, but causes significant gastrointestinal and hematologic adverse effects. 1

Gastrointestinal Effects (Most Common)

  • Gastritis, nausea, diarrhea, and abdominal pain are the most frequent side-effects 1
  • These GI effects are dose-limiting in many patients 1
  • An enteric-coated formulation (mycophenolate sodium/EC-MPS) was developed to reduce GI side effects by delaying release until the small intestine 1

Hematologic Effects

  • Bone marrow suppression leading to leukopenia, anemia, and thrombocytopenia 1
  • Regular monitoring of complete blood counts is essential 2

Infectious and Malignancy Risk

  • Increased susceptibility to infections (though less than with higher-dose tacrolimus alone) 4
  • Possible increased risk of malignancy (shared with all immunosuppressants) 1

Important Drug Interaction

  • Allopurinol can increase MMF/azathioprine levels to toxic levels and should be avoided or used with extreme caution 1

Advantages Over Other Agents

  • No nephrotoxicity, making it valuable for renal-sparing strategies 1, 5
  • No cholestatic hepatitis (unlike azathioprine) 1
  • Does not cause gingival hyperplasia or significant dyslipidemia 1

Basiliximab Side Effects

Basiliximab (an IL-2 receptor antagonist) has an exceptionally favorable safety profile with minimal side effects compared to other induction agents. 1, 3

Safety Profile

  • No significant increase in opportunistic infections when added to triple immunosuppression 6
  • No increase in malignancy risk in short-term studies 4
  • Side-effect profile is not significantly different from placebo in most trials 4
  • Significantly fewer side effects than lymphocyte-depleting agents (OKT3, ATG) 4

Clinical Benefits

  • Reduces acute rejection rates by approximately 15% without adding toxicity 4
  • Allows reduction of tacrolimus doses, thereby reducing tacrolimus nephrotoxicity 6
  • Does not delay wound healing (unlike mTOR inhibitors) 1, 3

Rare Adverse Events

  • Hypersensitivity reactions are possible but rare 4
  • No specific organ toxicity has been identified 4

Comparative Safety Considerations

Synergistic Toxicities to Avoid

  • Tacrolimus + sirolimus: synergistic nephrotoxicity with significantly worse long-term graft function and survival compared to tacrolimus + MMF 7
  • Tacrolimus + NSAIDs: potentiated nephrotoxicity 1
  • MMF/azathioprine + allopurinol: risk of severe bone marrow toxicity 1

Optimal Safety Strategy

The combination of tacrolimus + MMF + basiliximab induction provides the best balance of efficacy and safety 3, 6:

  • Basiliximab reduces rejection without adding toxicity 6, 4
  • MMF allows lower tacrolimus doses, reducing nephrotoxicity 5
  • This triple regimen with basiliximab induction is recommended by the American Society of Transplantation as standard for low-to-moderate risk patients 3

Common Pitfall

Do not combine tacrolimus with sirolimus or everolimus in the early post-transplant period, as this causes synergistic nephrotoxicity, higher rejection rates, and worse graft survival 1, 7. If mTOR inhibitors are needed, they should not be started until graft function is established and surgical wounds are healed 1, 3.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Guideline

Tacrolimus Target Levels and Monitoring in Renal Transplant Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Immunosuppression Regimens in Post-Renal Transplant Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended immunosuppressive regimen for renal transplant patients in North America?
What adjustments should be made to immunosuppression with mycophenolate (Cellcept) and tacrolimus (Prograf) in a renal transplant patient with advanced renal failure and volume overload?
What are the laboratory monitoring requirements for mycophenolate (Cellcept) therapy?
What is the difference between atracurium and rocuronium for a patient taking Mycophenolate Mofetil (Cellcept) with potential impaired renal function undergoing surgery?
Do Mycophenolate Mofetil (MMF) and Nintedanib cause kidney injury?
In a 40-year-old woman with type 1 diabetes mellitus presenting with three months of non-bilious, food-containing vomiting and early satiety, normal vital signs and a soft, non-tender abdomen, what is the first-line pharmacologic therapy for her vomiting?
What is the appropriate management plan for a patient with newly diagnosed essential hypertension and alcohol use disorder?
What did the MERCURY studies demonstrate about the use of high‑resolution pelvic MRI for local staging of rectal cancer and its implications for neoadjuvant therapy and surgical planning?
In an 81‑year‑old woman admitted for acute‑on‑chronic congestive heart failure who now has bilateral pleural effusions on chest CT, what alternative diagnoses should be considered?
In a 44-year-old man with a 10‑day history of profuse watery, non‑bloody, greasy, foul‑smelling diarrhea and daycare exposure, which is the most appropriate therapy: ciprofloxacin, metronidazole, symptomatic care, or trimethoprim‑sulfamethoxazole?
What initial antihypertensive therapy should be started in an adult with newly diagnosed essential hypertension and alcohol‑use disorder who has blood pressure ≥160/100 mmHg after lifestyle modification?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question